Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dosing strategy aims to tackle lung cancer brain spread

NCT ID NCT07348965

Recruiting now Disease control Sponsor: Guangzhou University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 06, 2026 · Updated 18 times

Summary

This study is for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain (leptomeningeal metastasis). It tests whether taking a higher dose of the drug furmonertinib every other day works better and is safe compared to the standard daily dose. About 42 participants will choose either the every-other-day or daily regimen, and researchers will monitor tumor response, side effects, and drug levels in the blood and spinal fluid.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial Hospital of Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510120, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR ACTIVATING MUTATION EGFR ACTIVATING MUTATION FURMONERTINIB LEPTOMENINGEAL METASTASIS NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)